Highest-materiality recent filing
Edgewise Q2 net loss $57.3M; completes sevasemten sale to Servier for up to $2.65B
Net loss $57.3M ($0.53/share) vs $36.1M ($0.34) in Q2 2025; R&D $47.5M, G&A $14.4M.
Edgewise closes $1.55B sale of sevasemten to Servier; pivots to cardiovascular pipeline
Received $1.55B upfront cash; eligible for up to $1.1B in regulatory/commercial milestones.
Edgewise completes $1.55B sale of muscular dystrophy program to Servier; up to $2.65B total
Sold sevasemten and muscular dystrophy program to Servier for $1.55B upfront plus up to $1.1B in milestones ($2.65B total).
Edgewise sells sevasemten to Servier for $1.55B upfront, plus up to $1.1B milestones
$1.55B upfront cash; potential $1.1B in regulatory and commercial milestones totaling up to $2.65B.
Edgewise Q1 net loss $49M, cash $499.6M; sevasemten Becker data up to 3.5 years
Net loss $49.0M ($0.46/share) in Q1 2026 vs $40.8M ($0.43/share) in Q1 2025; cash and equivalents $499.6M.
Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026
Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.
Edgewise Q3 net loss $40.7M ($0.39/sh); cash $563.3M; GRAND CANYON data Q4 2026
Cash, equivalents and marketable securities $563.3M at Sep 30, 2025.
Edgewise Q2 net loss $36.1M; positive sevasemten data in Becker, Duchenne
Net loss of $36.1M ($0.34/share) for Q2 2025; cash and equivalents $594M as of June 30.
Edgewise announces positive sevasemten data; FDA provides clear path to first Becker therapy
MESA OLE: 99% enrollment (85 participants); NSAA scores improved 0.8 pts over 18 months, diverging from natural history declines.
Edgewise Q1 net loss $40.8M; positive Phase 2 HCM data and $188M offering highlighted
Positive top-line data from Phase 2 CIRRUS-HCM: EDG-7500 reduced LVOT-G without meaningful LVEF changes; improved KCCQ and NT-proBNP.
Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest
Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.
Edgewise Therapeutics prices $200M common stock offering at $20.13 per share
9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.
Primary endpoint met: CK decreased 28% vs placebo over months 6-12 in adults (p=0.02).
Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete
Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.
Edgewise Therapeutics enters $175M ATM equity offering with Leerink Partners
New Sales Agreement with Leerink Partners for at-the-market offering of up to $175M common stock.
Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data
Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.
Edgewise posts Q4 net loss $0.47/sh; pro-forma cash >$550M; multiple trial readouts in 2024
Net loss for Q4 2023 was $30.1M ($0.47 per share), up from $25.7M ($0.41) in Q3 2023.
Edgewise Therapeutics announces $240M underwritten offering of 21.8M shares at $11.00 each
Gross proceeds ~$240M from offering of 21.8M shares at $11.00; closing expected Jan 23, 2024.
Edgewise reports Q2 2023 net loss $21.5M; positive ARCH 12-month data for EDG-5506
Cash, equivalents and marketable securities $310M as of June 30, 2023.
Edgewise Q3 net loss $17.5M ($0.34/shr); cash $365M; EDG-5506 shows biomarker reductions
Cash, equivalents and marketable securities $365M as of Sept 30, 2022; underwritten offering raised $129M net.
Underwritten 11,627,907 shares; underwriters have 30-day option for additional 1,744,186 shares.
Edgewise announces FDA authorization for Phase 2 DMD trial; positive ARCH interim data in BMD
FDA authorized Phase 2 LYNX trial of EDG-5506 in children with DMD; dosing expected Q4 2022.
Edgewise reports Q2 net loss $0.32/sh; positive EDG-5506 BMD interim data
Cash and equivalents $248.4M as of June 30; expected to fund operations through end of 2024.
Edgewise reports Q4 2021 net loss $12.7M, cash $281M; EDG-5506 Phase 1b positive
Net loss Q4 2021 $12.7M ($0.26/share); full year net loss $42.8M ($1.14/share).
Edgewise reports positive Phase 1b results for EDG-5506 in Becker MD: biomarkers reduced 71-83%
EDG-5506 well tolerated with no serious adverse events; dizziness was mild and transient.
Edgewise reports Q3 net loss $12.9M; positive Phase 1 MAD data for EDG-5506
Cash, cash equivalents and marketable securities of $290M as of Sept 30, 2021.
Edgewise reports positive Phase 1 MAD results for EDG-5506; Phase 2 in BMD and DMD planned for 2022
EDG-5506 generally well tolerated; no serious adverse events; mild dizziness/somnolence resolved.
Edgewise Therapeutics Q2 net loss $10.4M; cash $299M; EDG-5506 advancing
Net loss of $10.4M ($0.21 per share) for Q2 2021, up from $4.0M loss in Q2 2020; R&D expenses $7.9M.
On January 8, 2025, the Board of Directors (the “ Board ”) of Edgewise Therapeutics, Inc. (the “ Company ”) promoted Behrad Derakhshan, Ph.D. to the role of Chief Operating Officer of the Company, effective immediately.
On May 6, 2024, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee.
On June 19, 2023, Kenneth Harrison, Ph.D. informed the Board that he was resigning from the Board and all of its committees, effective on such date
On March 2, 2023, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Dr. Jonathan Fox to serve (i) as a Class III director, with a term expiring at the Company’s 2024 annual meeting of stockholders, and (ii) as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).
Max materiality 1.00 · Median 0.62 · Most common event earnings